Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...

A few baseline characteristics can predict the need for recurrent endoscopic sinus surgery (ESS) among patients with chronic rhinosinusitis with nasal polyps (CRSwNP), according to a study published ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 million people in the country. This approval ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

Concerning CRSwNP, GSK intends to secure approval in adults. Similar regulatory filings for the drug have also been validated for review in China and Japan. If approved, depemokimab will be the ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...